迪哲医药高瑞哲和Birelentinib多项研究入选第67届ASH大会

Core Insights - DiZhe Pharmaceutical (688192) will present multiple latest research findings on its key lymphoma treatment products, Golixty (generic name: Golixty capsules) and Birelentinib (DZD8586), at the 67th American Society of Hematology (ASH) conference from December 6 to 9 [1] Group 1: Product Developments - The ASH conference will showcase Golixty's exploration and progress in monotherapy and combination therapy strategies for r/r PTCL, first-line treatment, and rare subtypes, highlighting its broad application potential in T-cell lymphoma treatment [1] - Birelentinib is a globally innovative non-covalent dual-target inhibitor of LYN/BTK that can fully penetrate the blood-brain barrier, with the latest data from I/II clinical studies in CLL/SLL patients previously treated with covalent or non-covalent BTK inhibitors and BTK degraders to be presented [1]